166 related articles for article (PubMed ID: 37823731)
1. Hypoxia-Directed and Self-Immolative Theranostic Agent: Imaging and Treatment of Cancer and Bacterial Infections.
Karan S; Cho MY; Lee H; Kim HM; Park HS; Han EH; Sessler JL; Hong KS
J Med Chem; 2023 Oct; 66(20):14175-14187. PubMed ID: 37823731
[TBL] [Abstract][Full Text] [Related]
2. A light-activatable theranostic combination for ratiometric hypoxia imaging and oxygen-deprived drug activity enhancement.
Ge L; Tang Y; Wang C; Chen J; Mao H; Jiang X
Nat Commun; 2024 Jan; 15(1):153. PubMed ID: 38167737
[TBL] [Abstract][Full Text] [Related]
3. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
4. A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy.
Yang Z; Lin H; Huang J; Li A; Sun C; Richmond J; Gao J
Chem Commun (Camb); 2019 Apr; 55(31):4546-4549. PubMed ID: 30924831
[TBL] [Abstract][Full Text] [Related]
5. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
Zhao XB; Gao K; Shi YP
Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
[TBL] [Abstract][Full Text] [Related]
6. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control.
Feng W; Gao C; Liu W; Ren H; Wang C; Ge K; Li S; Zhou G; Li H; Wang S; Jia G; Li Z; Zhang J
Chem Commun (Camb); 2016 Aug; 52(60):9434-7. PubMed ID: 27379361
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Peng X; Gao J; Yuan Y; Liu H; Lei W; Li S; Zhang J; Wang S
Bioconjug Chem; 2019 Nov; 30(11):2828-2843. PubMed ID: 31592652
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the Release Efficiency of a Molecular Chemotherapeutic Prodrug by Photodynamic Therapy.
Yuan J; Zhou QH; Xu S; Zuo QP; Li W; Zhang XX; Ren TB; Yuan L; Zhang XB
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202206169. PubMed ID: 35688800
[TBL] [Abstract][Full Text] [Related]
10. Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.
Feng L; Cheng L; Dong Z; Tao D; Barnhart TE; Cai W; Chen M; Liu Z
ACS Nano; 2017 Jan; 11(1):927-937. PubMed ID: 28027442
[TBL] [Abstract][Full Text] [Related]
11. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
[TBL] [Abstract][Full Text] [Related]
12. A new self-immolative colistin prodrug with dual targeting functionalities and reduced toxicity for the treatment of intracellular bacterial infections.
Liu G; Lu D; Zhu S; Hao M; Yang X; Wang X; Zhang Y
J Biomed Mater Res A; 2022 Sep; 110(9):1590-1598. PubMed ID: 35593460
[TBL] [Abstract][Full Text] [Related]
13. Zwitterionic rhodamine-CPT prodrug nanoparticles with GSH/H
Mu X; Huang Z; Feng W; Zhai M; Wang Y; Zhou D; Zhou X
Theranostics; 2023; 13(1):267-277. PubMed ID: 36593965
[No Abstract] [Full Text] [Related]
14. Advances in Multifunctional Chemotherapeutic Prodrugs for Near-infrared Fluorescence Imaging-guided Therapy.
Zeng J; Liu M; Li S; Cheng D; He L; Yuan L
Chembiochem; 2023 Jun; 24(12):e202300035. PubMed ID: 36802094
[TBL] [Abstract][Full Text] [Related]
15. Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy.
Zhou Y; Maiti M; Sharma A; Won M; Yu L; Miao LX; Shin J; Podder A; Bobba KN; Han J; Bhuniya S; Kim JS
J Control Release; 2018 Oct; 288():14-22. PubMed ID: 30170068
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor.
Kumar R; Kim EJ; Han J; Lee H; Shin WS; Kim HM; Bhuniya S; Kim JS; Hong KS
Biomaterials; 2016 Oct; 104():119-28. PubMed ID: 27449948
[TBL] [Abstract][Full Text] [Related]
17. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
Song X; Han X; Yu F; Zhang X; Chen L; Lv C
Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Activated Anticancer Prodrug for Bioimaging, Tracking Drug Release, and Anticancer Application.
Liu W; Liu H; Peng X; Zhou G; Liu D; Li S; Zhang J; Wang S
Bioconjug Chem; 2018 Oct; 29(10):3332-3343. PubMed ID: 30192132
[TBL] [Abstract][Full Text] [Related]
19. COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models.
Kim HS; Sharma A; Ren WX; Han J; Kim JS
Biomaterials; 2018 Dec; 185():63-72. PubMed ID: 30223141
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment.
Yuan X; Xie Z; Zou T
Bioorg Chem; 2024 Mar; 144():107161. PubMed ID: 38306826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
